FY27-28 Adult Flu Vaccines
Archived on October 1, 2026. Combined Synopsis/Solicitation posted by HEALTH AND HUMAN SERVICES, DEPARTMENT OF (CENTERS FOR DISEASE CONTROL AND PREVENTION) on September 9, 2026. Solicitation 75D30126R73517.
NAICS 325412 (Pharmaceutical Preparation Manufacturing). Set-aside: No Set aside used. Place of performance: Atlanta, Georgia. Original response deadline: . Full description on SAM.gov.
Description
The Centers for Disease Control and Prevention (CDC) awards one or more Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts for the purchase of standard commercial adult vaccines. The establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial marketplace. These funds provide vaccines for state and local health departments to use in populations at greatest risk for under vaccination and disease. The 317 program as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate immunization by partnering with healthcare providers in the public and private sectors. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage. The vaccines awarded under these contracts will be purchased for the National Center for Immunization and Respiratory Disease’s (NCIRD’s) immunization awardees (the fifty state health departments, several large city programs, and current and former U.S. Territories) to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act. In addition, awardees may opt to purchase additional quantities of vaccine for adults under any resulting contract using state and local funds.
Overview
Award Overview
Possible prior contracts
Sign in to see possible prior contracts for this requirement (matched by agency, NAICS and place of performance; not confirmed).
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Documents
Showing 8 of 8 items
Document | Source | Agency | Posted Date | File Size | Actions | |
|---|---|---|---|---|---|---|
| Combined Synopsis/Solicitation | CENTERS FOR DISEASE CONTROL AND PREVENTION | Sep 9, 2026 | 16.74 KB | |||
| Combined Synopsis/Solicitation | CENTERS FOR DISEASE CONTROL AND PREVENTION | Sep 9, 2026 | 97.11 KB | |||
| Combined Synopsis/Solicitation | CENTERS FOR DISEASE CONTROL AND PREVENTION | Sep 9, 2026 | 16.58 KB | |||
| Combined Synopsis/Solicitation | CENTERS FOR DISEASE CONTROL AND PREVENTION | Sep 9, 2026 | 17.44 KB | |||
| Combined Synopsis/Solicitation | CENTERS FOR DISEASE CONTROL AND PREVENTION | Sep 9, 2026 | 689.11 KB | |||
| Combined Synopsis/Solicitation | CENTERS FOR DISEASE CONTROL AND PREVENTION | Sep 9, 2026 | 25.52 KB | |||
| Combined Synopsis/Solicitation | CENTERS FOR DISEASE CONTROL AND PREVENTION | Sep 9, 2026 | 699.4 KB | |||
| Combined Synopsis/Solicitation | CENTERS FOR DISEASE CONTROL AND PREVENTION | Sep 9, 2026 | 116.14 KB |
Lifecycle
75D30126R73517- Combined Synopsis
- 2×Combined SynopsisCurrentSep 2, 2026
FY27-28 Adult Flu Vaccines
Similar Opportunities
Title | Phase | Agency | NAICS | Set Aside | Posted | Deadline | Location |
|---|---|---|---|---|---|---|---|
The Corporal Michael J. Crescenz VA Medical Center (CMCVAMC) is seeking a licensed vendor, accredited by the Nuclear Regulatory Commission, to provide essential radiopharmaceuticals and calibration sources for its Nuclear Medicine Department for a five-year ordering period. These supplies are critical for performing imaging procedures and ensuring equipment quality control. | Solicitation | 325412 | No Set-Aside | 10/14/2026 | 10/15/2026 | - | |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | Solicitation | 325412 | No Set-Aside | 10/08/2026 | 10/26/2026 | San Antonio, TX | |
The Corporal Michael J. Crescenz VA Medical Center (CMCVAMC) is seeking a licensed vendor, accredited by the Nuclear Regulatory Commission, to provide essential radiopharmaceuticals and calibration sources for its Nuclear Medicine Department for a five-year ordering period. These supplies are critical for performing imaging procedures and ensuring equipment quality control. | Solicitation | 325412 | No Set-Aside | 10/08/2026 | 10/15/2026 | - | |
The contract was not awarded competitively in accordance with Revolutionary FAR Overhaul (RFO) 12.102(a) - acquisitions valued at or below the simplified acquisition threshold. | Awarded | 325412 | No Set-Aside | 10/06/2026 | Open | Colorado Springs, CO | |
Awardee: NOVARTIS PHARMACEUTICALS CORPORATION Award Amount: $4,115,311.20 Period of Performance: 10/1/2026 - 09/30/2027 Limited Source Justification Attached | Awarded | 325412 | No Set-Aside | 10/01/2026 | Open | Palo Alto, CA |
Additional Details
Solicitation Number
75D30126R73517
Archive Date
Oct 1, 2026
Office Address
ATLANTA, GA, 30333